Avidity Partners Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Avidity Partners Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,053,300	Closed	-$13.2M	–	82
2024 Q4	$13.2M	Buy	1,053,300 +304,300	+41%	+$4.58M	1.3%	34
2024 Q3	$13.8M	Sell	749,000 -351,000	-32%	-$7.19M	0.71%	53
2024 Q2	$23.7M	Buy	1,100,000 +75,000	+7%	+$1.72M	1.01%	43
2024 Q1	$27.6M	Sell	1,025,000 -694,103	-40%	-$19.7M	0.89%	40
2023 Q4	$51.5M	Buy	1,719,103 +131,674	+8%	+$2.91M	1.88%	20
2023 Q3	$32.5M	Buy	1,587,429 +261,429	+20%	+$4.75M	1.31%	36
2023 Q2	$26.3M	Buy	1,326,000 +81,600	+7%	+$1.65M	0.92%	45
2023 Q1	$21.3M	Sell	1,244,400 -282,687	-19%	-$5.54M	0.71%	45
2022 Q4	$29.9M	Buy	+1,527,087	New	+$28.1M	0.65%	44
2021 Q1	–	Sell	-50,000	Closed	-$2.74M	–	119
2020 Q4	$2.74M	Buy	+50,000	New	+$1.82M	0.09%	89
2020 Q1	–	Sell	-30,000	Closed	-$683K	–	62
2019 Q4	$683K	Buy	+30,000	New	+$501K	0.43%	30

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Avidity Partners Management's RCKT Position: Q1 2025 in Review

Avidity Partners Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2025, closing a stake of 1,053,300 shares — an estimated $13.2M sold.

Avidity Partners Management first reported a position in RCKT in Q4 2019 and held it in 11 quarters. The position peaked at $51.5M in Q4 2023. 236 funds tracked by Wall St. Rank hold RCKT as of Q1 2025.

Avidity Partners Management reported no remaining Rocket Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Avidity Partners Management sold 1,053,300 Rocket Pharmaceuticals shares in Q1 2025, an estimated $13.2M.
Avidity Partners Management first reported a position in Rocket Pharmaceuticals in Q4 2019 and held it in 11 quarters.
Avidity Partners Management's Rocket Pharmaceuticals position peaked at $51.5M in Q4 2023.
236 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2025.

Based on Avidity Partners Management's 13F filing for Q1 2025, filed 15 May 2025.